换一批Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
第一作者：
Anne S,Tsao
第一单位：
Department of Thoracic/Head & Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. astsao@mdanderson.org
作者：
医学主题词
成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);苯甲酰胺类(Benzamides);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);癌, 鳞状细胞(Carcinoma, Squamous Cell);卡方分布(Chi-Square Distribution);无病生存(Disease-Free Survival);临床试验早期终止(Early Termination of Clinical Trials);女(雌)性(Female);基因剂量(Gene Dosage);头颈部肿瘤(Head and Neck Neoplasms);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);肺肿瘤(Lung Neoplasms);男(雄)性(Male);中年人(Middle Aged);哌嗪类(Piperazines);比例危险度模型(Proportional Hazards Models);原癌基因蛋白质c-sis(Proto-Oncogene Proteins c-sis);嘧啶类(Pyrimidines);受体, 血小板源生长因子α(Receptor, Platelet-Derived Growth Factor alpha);受体, 血小板源生长因子β(Receptor, Platelet-Derived Growth Factor beta);紫杉烷类(Taxoids)
DOI
10.1097/JTO.0b013e31822e7256
PMID
21892101
发布时间
2023-02-02
- 浏览39
Journal of thoracic oncology
2104-11页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
